Chinese biotechnology firm Zhongyianke Biotech announced on Thursday that it has raised RMB250 million (US$36.35 million) in a series A round of financing from a group of investors including Chinese investment firm Shenzhen Qianhai Beizeng Asset Management.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!Register Now
Already have an account or paid subscription?